Oncology · Small MoleculeRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Lenalidomide ANDA217265 by QILU

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/30/2026, 12:31:35 PM

Assessment confidence: 54% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval status for QILU's lenalidomide ANDA217265 signifies a potential increase in market competition, which could impact pricing and market share for existing lenalidomide products. Portfolio teams need to evaluate the implications of this approval on their strategies. Regulatory context from FDA (FDA AP — REVLIMID (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of QILU's entry on market share and pricing strategies for lenalidomide products. The strongest clinical anchor is A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (ClinicalTrials.gov), mechanism alignment (io ). In Oncology · Small Molecule, 5 regulatory and 4 competitive items passed relevance filtering for QILU.

Competitive Pressure

The most relevant competitive pressure comes from Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer. This approval status may allow QILU to enter the market with a generic version of lenalidomide, increasing competition against established brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — REVLIMID (SUPPL) (FDA). Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda). While the approval status is a positive step for QILU, the final approval and subsequent market launch will be critical to understand the full regulatory implications.

Key Risks

Elevated medium regulatory exposure for QILU could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

QILU's entry into the market with a generic version of lenalidomide could lead to price reductions and shifts in market share, affecting revenue for established brands.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Portfolio teams should assess the impact of QILU's entry on market share and pricing strategies for lenalidomide products.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timeline of QILU's lenalidomide product.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — PADCEV (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lenalidomide for Adult Histiocyte Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Karyopharm's XPOVIO (Selinexor) NDA212306 Receives Approval Status from FDA
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves JIDEYTRO (ZIDESAMTINIB) for Nuvalent Inc.
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Thalidomide Application ANDA213267
Humanexa Signalsmedium relevance
Moderate corpus alignment

Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

QILU

Commercial impact

medium

QILU's entry into the market with a generic version of lenalidomide could lead to price reductions and shifts in market share, affecting revenue for established brands.

Regulatory impact

medium

While the approval status is a positive step for QILU, the final approval and subsequent market launch will be critical to understand the full regulatory implications.

What to watch

Monitor for the final approval and market launch timeline of QILU's lenalidomide product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.